Two days after filing their cancer drug lurbinectedin in the hunt for an FDA approval, Spain’s PharmaMar has snagged $200 million in cash as a down payment for a new pact with a US partner.
Jazz is handing off the cash and promising $800 million more in a billion-dollar bet that the drug can carve a straight path from positive Phase II data right into the lucrative market for small cell lung cancer — a tough field for drug hunters. Out of the $800 million, $250 million is reserved for regulatory approvals as they steer the drug to a potential 2020 launch.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,